Who is sponsoring NCT01620307?

NCT01620307 is sponsored by Chang Gung Memorial Hospital.

What condition does NCT01620307 study?

NCT01620307 studies H1N1 Pneumonia, Hypoxemia.

What drugs are being tested in NCT01620307?

Interventions: Sirolimus (Rapamune 2mg/day, Pfizer).

What is the status of NCT01620307?

NCT01620307 is currently COMPLETED.

Last reviewed 2012-06-14 · How we verify

Adjuvant Treatment With a mTOR Inhibitor, Rapamune Improves Outcomes of Severe H1N1 Pneumonia With Acute Respiratory Failure

NCT01620307 Phase 2 COMPLETED

Severe H1N1 pneumonia with acute respiratory failure shows hyperactive immune cells infiltration of lung. Rapamune, a mTOR inhibitor, modulates the immune response by blocking activation of T- and B-cells. To investigate the clinical efficiency of rapamune in severe H1N1 pneumonia with respiratory failure, this study was conducted.

Details

Lead sponsor	Chang Gung Memorial Hospital
Phase	Phase 2
Status	COMPLETED
Enrolment	38
Start date	2009-06
Completion	2011-12

Conditions

H1N1 Pneumonia
Hypoxemia

Interventions

Sirolimus (Rapamune 2mg/day, Pfizer)

Primary outcomes

liberation of ventilator — 28 days
Patients were then randomized to receive either Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days. Ventilator management was previously described. The ventilator liberation rate is primary outcome.